ITRM Logo

Iterum Therapeutics plc (ITRM) 

NASDAQ
Market Cap
$20.2M
Sector
Healthcare
Industry
Biotechnology
Rank in Sector
265 of 809
Rank in Industry
156 of 445

Largest Insider Buys in Sector

ITRM Stock Price History Chart

ITRM Stock Performance

About Iterum Therapeutics plc

Iterum Therapeutics plc, a clinical-stage pharmaceutical company, engages in developing and commercializing anti-infectives in Ireland, Bermuda, and the United States. It is developing sulopenem, a novel anti-infective compound with oral and IV formulations that is in Phase III clinical trials for the treatment of uncomplicated urinary tract infections, complicated urinary tract infections, and complicated intra-abdominal infections. The company was incorporated in 2015 and is headquartered in Dublin, Ireland.

Insider Activity of Iterum Therapeutics plc

Over the last 12 months, insiders at Iterum Therapeutics plc have bought $109,995 and sold $0 worth of Iterum Therapeutics plc stock.

On average, over the past 5 years, insiders at Iterum Therapeutics plc have bought $74,998 and sold $12.8M worth of stock each year.

Highest buying activity among insiders over the last 12 months: Dunne Michael W. (director) — $94,132. Fishman Corey N. (Chief Executive Officer) — $15,863.

The last purchase of 25,000 shares for transaction amount of $35,000 was made by Dunne Michael W. (director) on 2023‑12‑22.

List of Insider Buy and Sell Transactions, Iterum Therapeutics plc

2023-12-22PurchaseDunne Michael W.director
25,000
0.1716%
$1.40$35,000+9.94%
2023-12-18PurchaseDunne Michael W.director
10,000
0.0794%
$1.84$18,442-11.93%
2023-11-22PurchaseDunne Michael W.director
20,000
0.1507%
$2.03$40,690-24.28%
2023-11-20PurchaseFishman Corey N.Chief Executive Officer
10,000
0.0872%
$1.59$15,863+13.26%
2022-12-02SalePuttagunta SailajaChief Medical Officer
3,365
0.0261%
$1.32$4,442-23.02%
2022-03-14SaleMatthews Judith M.Chief Financial Officer
63,340
0.029%
$0.31$19,635-62.16%
2022-03-11SaleMatthews Judith M.Chief Financial Officer
47,132
0.0261%
$0.38$17,910-61.07%
2021-02-12SaleDENNER ALEXANDER J10 percent owner
10.62M
8.7758%
$2.27$24.11M-69.11%
2021-02-11SaleDENNER ALEXANDER J10 percent owner
10M
9.0673%
$2.59$25.9M-70.30%
2021-01-26SaleFishman Corey N.President & CEO
170,890
0.077%
$0.86$147,820-49.75%
2021-01-26SaleDunne Michael W.director
33,143
0.0299%
$1.73$57,337-49.75%
2021-01-26SaleMatthews Judith M.Chief Financial Officer
33,868
0.0305%
$1.73$58,592-49.75%
2020-10-27PurchaseDunne Michael W.Chief Scientific Officer
123,080
0.3428%
$0.33$40,001+124.28%
2020-09-30SaleMatthews Judith M.Chief Financial Officer
112,260
0.3651%
$0.82$92,053+5.71%
2020-06-02SaleSofinnova Venture Partners IX, L.P.10 percent owner
800,000
2.5418%
$0.80$642,960-32.10%
2020-06-01SaleSofinnova Venture Partners IX, L.P.10 percent owner
200,000
0.6371%
$0.85$169,120-35.29%
2018-11-30PurchaseKelly David Georgedirector
20,000
0.1148%
$3.14$62,887+2.19%
2018-10-30PurchaseChin Markdirector
116,000
1.3004%
$6.10$707,600+3.21%
2018-09-04PurchaseDunne Michael W.Chief Scientific Officer
1,000
0.0038%
$5.00$5,000-30.64%
2018-08-27PurchaseDunne Michael W.Chief Scientific Officer
1,000
0.0071%
$10.00$10,000-34.86%

Insider Historical Profitability

124.28%
Dunne Michael W.director
113754
0.8477%
$1.2281+124.28%
Fishman Corey N.Chief Executive Officer
54449
0.4058%
$1.2231
CANAAN X L.P.
1733170
12.9163%
$1.2210
Ahrens Brenton Karldirector
1733170
12.9163%
$1.2210
HEALY JAMES
1726514
12.8667%
$1.2210
Sofinnova Venture Partners IX, L.P.10 percent owner
1226514
9.1405%
$1.2212
Heron Patrick Jdirector
1197161
8.9217%
$1.2210
Chin Markdirector
1089903
8.1224%
$1.2220
HUNT RONALD
1071688
7.9866%
$1.2210
Lathi Vijay K10 percent owner
1071688
7.9866%
$1.2210
Malik Shahzaddirector
838325
6.2475%
$1.2210
Matthews Judith M.Chief Financial Officer
65292
0.4866%
$1.2214
Edick Paul Rdirector
25236
0.1881%
$1.2210
Kelly David Georgedirector
19548
0.1457%
$1.2210
Puttagunta SailajaChief Medical Officer
4969
0.037%
$1.2201
DENNER ALEXANDER J10 percent owner
0
0%
$1.2202

Institutional Investor Ownership

Top Shareholders
Top Buyers
Top Sellers
New Shareholders
Sold-Out Shareholders
No records found…